March 10, 2026 at 1PM EST

The 340B landscape is at a critical inflection point. Ongoing litigation around contract pharmacy policies and rebate model continues to create uncertainty, while powerful market and policy forces—including Medicaid’s uncapped rebate structure, the Inflation Reduction Act (IRA), voluntary government initiatives like GENEROUS, and WAC reductions—are rapidly reshaping manufacturer strategy.

Manufacturers are now challenged to move beyond legacy approaches that deliver diminishing returns or are stalled by litigation, and toward smarter, sustainable strategies that address 340B growth and misuse while preserving program stability.

Join Clay Willis, Partner of Advisory Services, for this timely webinar as he breaks down the latest developments in rebate models, contract pharmacy and in-house pharmacy policies, and other critical market shifts. Clay will also highlight alternative, forward-looking strategies—often overlooked—that manufacturers can leverage to navigate today’s complexity and position for what’s next.

Clay Willis
Partner, Advisory Services